The Hatch–Waxman Act aims to strike a balance between the innovation incentives provided by patents and the greater access provided by generic drugs. Now the tactical landscape in the drug-patent wars has shifted again, with a recently decided Supreme Court case.
No takes yet. Share an insight, caveat, or question.
Arti Kaur Rai (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: